A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Lanreotide (Primary)
- Indications Fistula
- Focus Therapeutic Use
- 09 Oct 2018 Planned End Date changed from 1 Oct 2021 to 1 Apr 2021.
- 09 Oct 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Apr 2020.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.